These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 27561804)

  • 1. [Analysis of Clinicopathological Feature and Prognosis for 
Leptomeningeal Metastasis in Non-small Cell Lung Cancer].
    Zhu M; Ren Y; Liu Y; Ban C; Gu H; Wang Z; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):533-8. PubMed ID: 27561804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
    Wu YL; Zhao Q; Deng L; Zhang Y; Zhou XJ; Li YY; Yu M; Zhou L; Zou BW; Lu Y; Liu YM
    Lung Cancer; 2019 Jan; 127():1-5. PubMed ID: 30642536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
    Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
    Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute.
    Yan W; Jing W; An N; Tian Y; Guo D; Kong L; Zhu H; Yu J
    Cancer Med; 2019 Jun; 8(6):2769-2776. PubMed ID: 30993909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations.
    Li YS; Jiang BY; Yang JJ; Tu HY; Zhou Q; Guo WB; Yan HH; Wu YL
    J Thorac Oncol; 2016 Nov; 11(11):1962-1969. PubMed ID: 27539328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.
    Flippot R; Biondani P; Auclin E; Xiao D; Hendriks L; Le Rhun E; Leduc C; Beau-Faller M; Gervais R; Remon J; Adam J; Planchard D; Lavaud P; Naltet C; Caramella C; Le Pechoux C; Lacroix L; Gazzah A; Mezquita L; Besse B
    J Thorac Oncol; 2019 Aug; 14(8):1400-1407. PubMed ID: 31108248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial.
    Lu ZQ; Cai J; Wang X; Wei JP; Zeng ZM; Huang L; Liu AW
    Thorac Cancer; 2021 Jan; 12(2):172-180. PubMed ID: 33205587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.
    Yan W; Liu Y; Li J; Han A; Kong L; Yu J; Zhu H
    Radiat Oncol; 2019 Sep; 14(1):168. PubMed ID: 31521171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal Metastasis.
    Wu Y; Zhao Y; Wu Y; Chen H; Ma S; Wang Q
    Clin Lung Cancer; 2024 Jun; 25(4):347-353.e1. PubMed ID: 38418264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
    Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
    Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
    Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.
    Liao BC; Lee JH; Lin CC; Chen YF; Chang CH; Ho CC; Shih JY; Yu CJ; Yang JC
    J Thorac Oncol; 2015 Dec; 10(12):1754-61. PubMed ID: 26334749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Epidermal growth factor tyrosine kinase inhibitors used in the treatment of NSCLC patients with leptomeningeal metastasis].
    Xu Y; Zhong W; Zhao J; Chen MJ; Zhang L; Li LY; Wang MZ
    Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):920-924. PubMed ID: 27998469
    [No Abstract]   [Full Text] [Related]  

  • 14. Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
    Tamiya A; Tamiya M; Nishihara T; Shiroyama T; Nakao K; Tsuji T; Takeuchi N; Isa SI; Omachi N; Okamoto N; Suzuki H; Okishio K; Iwazaki A; Imai K; Hirashima T; Atagi S
    Anticancer Res; 2017 Aug; 37(8):4177-4182. PubMed ID: 28739703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy.
    Morris PG; Reiner AS; Szenberg OR; Clarke JL; Panageas KS; Perez HR; Kris MG; Chan TA; DeAngelis LM; Omuro AM
    J Thorac Oncol; 2012 Feb; 7(2):382-5. PubMed ID: 22089116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
    Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
    Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.
    Wu H; Zhang Q; Zhai W; Chen Y; Yang Y; Xie M; Huang Z; Xu Y; Li H; Gong L; Yu S; Fan Y; Chen K
    Lung Cancer; 2024 Feb; 188():107475. PubMed ID: 38266613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
    Riess JW; Nagpal S; Iv M; Zeineh M; Gubens MA; Ramchandran K; Neal JW; Wakelee HA
    Clin Lung Cancer; 2014 May; 15(3):202-6. PubMed ID: 24524822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy.
    Xu Y; Hu M; Zhang M; Zhong W; Yin X; Sun Y; Chen M; Zhao J; Si X; Wang H; Zhang X; Zhang L; Li J; Guan H; Yang Z; Wang M
    Lung Cancer; 2018 Nov; 125():142-149. PubMed ID: 30429013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of molecular characteristics of cerebrospinal fluid for non-small cell lung cancer patients with leptomeningeal metastasis.
    Li N; Liu Y; Duan J; Yang B; Bai H; Sun R; Yu L; Wang J
    Thorac Cancer; 2019 Aug; 10(8):1673-1682. PubMed ID: 31368671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.